Shots:

• The companies enter into a clinical research collaboration for the evaluation of efficacy and safety of immunotherapy combining Roche’s Tecentriq (atezolizumab) with Immatics’ IMA101 in solid tumors
• In H2’19- companies plan for the onset of the trial based on ACTolog IMA101-101 study protocol at MD Anderson Cancer Center to kill cancer cells by blocking inhibitory immune checkpoints
• Tecentriq (atezolizumab) is a mAb inhibiting PD-L1 while blocking its interaction with PD-1 and B7.1 receptor. IMA101 is a P-I candidate based on Immatics’s ACTolog therapy (endogenous T-cell therapy) targeted for multiple advanced/ metastatic solid tumors

Ref: Immatics | Image: Roche